Skip to main content
NATR
NASDAQ Life Sciences

Nature's Sunshine Q2 Sales Rise 2%, but Net Income Falls 36% on FX Losses and Higher Tax Rate

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Food & Beverage Stocks · Consumer
Sentiment info
Negative
Importance info
7
Price
$17.95
Mkt Cap
$357.676M
52W Low
$12.973
52W High
$28.14
52W Position info
38% above low
Off High info
36% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

NATR sits 38% above its 52-week low of $12.973.

Summary

Nature's Sunshine Products posted a 2% sales increase in Q2 2026 but saw net income drop 36% due to foreign exchange losses and a higher tax rate. Operating cash flow turned negative, and an OFAC trade controls investigation remains unresolved.


Key Events · Earnings and Guidance · NATR

  • Q2 Sales Up 2%, Net Income Down 36%

    Net sales rose to $117.0 million from $114.8 million, but net income fell to $3.5 million from $5.5 million, driven by a $3.2 million swing in foreign exchange losses and a higher effective tax rate.

  • Operating Cash Flow Turns Negative

    For the first six months of 2026, operating activities used $1.0 million of cash, compared to generating $6.9 million in the prior year, due to lower net income and timing of working capital.

  • OFAC Trade Controls Disclosure Still Pending

    The company's voluntary self-disclosure to the Office of Foreign Assets Control (OFAC) regarding past trade controls violations remains unresolved; the BIS matter was closed without action.

  • Higher Tax Rate Weighs on Earnings

    The effective tax rate increased to 34.1% from 26.8%, primarily due to a valuation allowance on foreign tax credits and non-deductible executive compensation.


Analysis · NATR · Life Sciences

Nature's Sunshine Products reported Q2 2026 net sales of $117.0 million, a 1.9% increase from the prior year, driven by growth in Japan and North America. However, net income fell 35.9% to $3.5 million, pressured by a $3.2 million swing in foreign exchange losses and a higher effective tax rate. Operating cash flow turned negative for the first half of the year, and the company continues to navigate an ongoing OFAC voluntary disclosure related to trade controls. The results show a company growing its top line but facing margin and regulatory headwinds that are eroding profitability.

At the time of this filing, NATR was trading at $17.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $357.7M. The 52-week trading range was $12.97 to $28.14. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NATR - Latest Insights

NATR
Aug 06, 2026, 4:35 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $16.40
Real-time Price: $16.75 info
Change: +$0.350 (+2%) info
Market Cap: $357.676M info
NATR
May 11, 2026, 8:53 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $24.23
Real-time Price: $16.75 info
Change: -$7.48 (-31%) info
Market Cap: $357.676M info
NATR
May 11, 2026, 8:46 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $24.23
Real-time Price: $16.75 info
Change: -$7.48 (-31%) info
Market Cap: $357.676M info
NATR
May 07, 2026, 5:19 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $27.83
Real-time Price: $16.75 info
Change: -$11.08 (-40%) info
Market Cap: $357.676M info
NATR
May 07, 2026, 5:13 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $27.83
Real-time Price: $16.75 info
Change: -$11.08 (-40%) info
Market Cap: $357.676M info